Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects

NCT06025851 | Completed Phase 1 DMC

• 1 other identifier: CM-101-I-001
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

The study is designed to investigate the safety and tolerability of CM-101 for the treatment of medical conditions involving inflammatory and fibrotic mechanisms such as non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).

Conditions

Healthy

Outcome Measures

Primary Outcomes (6)

• Incidence and characteristics of adverse events (AEs) occurring following single doses of CM 101.

  Incidence and characteristics of adverse events (AEs) occurring following single doses of CM 101.

  1 day single-dose administration over 10 weeks

• Plasma Pharmacokinetic (PK) parameters of CM-101 - Maximum CM-101 plasma concentration (Cmax)

  Observed maximum plasma concentration

  1 day single-dose administration over 10 weeks

• Plasma Pharmacokinetic (PK) parameters of CM-101 - Time to Cmax (tmax)

  Time to reach the observed maximum plasma concentration (Tmax)

  1 day single-dose administration over 10 weeks

• Plasma Pharmacokinetic (PK) parameters of CM-101 - Area under the curve (AUC) to the final concentration ≥ limit of quantitation (LOQ), AUC(0-t) and to infinity AUCinf

  Area under the curve (AUC) to the final concentration ≥ limit of quantitation (LOQ), AUC(0-t) and to infinity AUCinf

  1 day single-dose administration over 10 week

• Plasma Pharmacokinetic (PK) parameters of CM-101 - Terminal elimination rate constant (λz)

  Elimination rate constant, determined by linear regression of the terminal points of the ln-linear plasma concentration-time curve

  1 day single-dose administration over 10 week

• Plasma Pharmacokinetic (PK) parameters of CM-101 - Terminal elimination half-life (T½)

  Terminal elimination half-life, defined as 0.693/λz

  1 day single-dose administration over 10 week

Secondary Outcomes (2)

• Assessment, based on the safety profile

  1 day single-dose administration over 10 week

• Level of antibodies against CM-101

  1 day single-dose administration over 10 week

Study Arms (2)

Anti-human CCL24 monoclonal antibody (CM-101)

EXPERIMENTAL

Anti-human CCL24 monoclonal antibody (CM-101) Four (4) treatment groups (0.75 mg/kg, 2.5 mg/kg, 5.0 mg/kg, 10 mg/kg)

Drug: Anti-human CCL24 monoclonal antibody (CM-101)

Placebo

PLACEBO COMPARATOR

Placebo - intravenous infusion

Drug: Placebo

Interventions

Anti-human CCL24 monoclonal antibody (CM-101) DRUG

Intravenous Infusion of Anti-human CCL24 monoclonal antibody (CM-101)

Anti-human CCL24 monoclonal antibody (CM-101)

Placebo DRUG

Placebo Comparator

Placebo

Eligibility Criteria

• Age: 18 Years - 45 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects must provide written informed consent prior to participating in the study.
• Considered healthy by the Investigator as defined by no clinically relevant abnormalities identified by a detailed medical history, full physical examination, 12-lead ECG and clinical laboratory tests.
• Body Mass Index (BMI) 19.0-29.0 kg/m2 and total body weight within 55-95 Kg.
• Fertile men must agree to use a barrier contraceptive (condom) for 90 days post-dosing and are restricted from donating sperm for 90 days after dosing. Subjects with a vasectomy performed more than 6 months prior to treatment are also acceptable.
• Non-smoking and no use of any tobacco or nicotine product by declaration for a period for at least 3 month prior to screening period.
• Supine blood pressure and heart rate within normal limits (systolic 90-140 mmHg; diastolic 50-90 mmHg, heart rate 45-100 beats per minute). No evidence of orthostatic hypotension.
• ECG with no clinically significant abnormalities recorded at Screening visit and on dosing day (before drug administration): PR interval within 120 and 210 ms, QRS interval \< 120 ms, and QTc interval \<450 ms.
• Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

You may not qualify if:

• Evidence or history of clinically relevant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies,). This includes any acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or CM-101 administration or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the subject inappropriate for entry into this study.
• History or current drug/alcohol abuse. History of regular alcohol consumption exceeding - 14 drinks/week for men (1 drink = 5 ounces \[150 mL\] of wine or 12 ounces \[360 mL\] of beer or 1.5 ounces \[45 mL\] of hard liquor) within 6 months of screening.
• Hypereosinophilia defined as peripheral blood Eosinophils \> 4.5×108/L (450/μl) or exceeding 7% of the circulating leukocytes.
• Positive urine drug of abuse (DoA) in screening and on admission.
• Positive breath alcohol test on admission.
• Known acute or chronic allergy to any drug or hypersensitivity to any of the test compounds or contraindication to test product.
• Use of any prescription or over-the-counter (OTC) medications, including vitamins and herbal or dietary supplements within 14 days prior to dosing. Paracetamol for symptomatic relief of pain is allowed until 24 hours prior to the study drug administration.
• Having received any biological treatment with recombinant antibodies, immunological therapy, or anticancer treatment. Previous standard vaccination treatment is allowed.
• Positive HIV, hepatitis HBsAg or hepatitis HCV Ab serology tests at Screening.
• Subjects who donated blood in the 3 months or received blood or plasma derivatives in the 6 months preceding study drug administration.
• Participation in another clinical trial within 3 months prior to dosing (calculated from the previous study's last dosing day).
• Subjects with any acute medical situation (e.g. acute infection) within 48 hours of dosing, which is considered of significance by the Principal Investigator
• Subjects with an inability to communicate well with the investigators and CRC staff (e.g., language problem, poor mental development).

Sponsors & Collaborators

• ChemomAb Ltd.: lead

Study Sites (1)

Tel Aviv Sourasky Medical Center

Tel Aviv, Israel

Location

MeSH Terms

Interventions

streptococcal polysaccharide type III group B

Study Officials

• Jacob Atsmon, MD

  Tel-Aviv Sourasky Medical Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 30, 2023
• First Posted: September 6, 2023
• Study Start: July 24, 2017
• Primary Completion: February 18, 2018
• Study Completion: February 18, 2018
• Last Updated: September 11, 2023

Record last verified: 2023-09

Data Sharing

• IPD Sharing: Will not share

Locations

IL (1)